MicroRNA-92a作为结直肠癌诊断的潜在生物标志物：一项系统评价和荟萃分析。
MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis.
作者信息
Yang Xin, Zeng Zongyue, Hou Yixuan, Yuan Taixian, Gao Chao, Jia Wei, Yi Xiaoyan, Liu Manran
机构信息
Key Laboratory of Laboratory Medical Diagnostics designated by Chinese Ministry of Education, Chongqing Medical University, Chongqing, China.
Key Laboratory of Laboratory Medical Diagnostics designated by Chinese Ministry of Education, Chongqing Medical University, Chongqing, China ; Experimental Teaching Center of Basic Medicine Science, Chongqing Medical University, Chongqing, China.
出版信息
PLoS One. 2014 Feb 14;9(2):e88745. doi: 10.1371/journal.pone.0088745. eCollection 2014.
INTRODUCTION
Previous studies demonstrated that MicroRNA-92a (miR-92a) was significantly differential expressed between colorectal cancer (CRC) patients and control cohorts, which provide timely relevant evidence for miR-92a as a novel promising biomarker in the colorectal cancer patients. This meta-analysis aimed to evaluate potential diagnostic value of plasma miR-92a.
METHODS
Relevant literatures were collected in PubMed, Embase, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI) and Technology of Chongqing (VIP), and Wan Fang Data. Sensitivity, specificity and diagnostic odds ratio (DOR) for miR-92a in the diagnosis of CRC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance.
RESULTS
This Meta-analysis included six studies with a total of 521 CRC patients and 379 healthy controls. For miR-92a, the pooled sensitivity, specificity and DOR to predict CRC patients were 76% (95% confidence interval [CI]: 72%-79%), 64% (95% confidence interval [CI]: 59%-69%) and 8.05 (95% CI: 3.50-18.56), respectively. In addition, the AUC of miR-92a in diagnosis CRC is 0.7720.
CONCLUSIONS
MicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.
引言
先前的研究表明，微小RNA-92a（miR-92a）在结直肠癌（CRC）患者与对照组之间存在显著差异表达，这为miR-92a作为结直肠癌患者一种新的有前景的生物标志物提供了及时的相关证据。本荟萃分析旨在评估血浆miR-92a的潜在诊断价值。
方法
在PubMed、Embase、中国生物医学文献数据库（CBM）、中国知网（CNKI）、重庆维普资讯（VIP）和万方数据中收集相关文献。使用随机效应模型汇总miR-92a在诊断CRC中的敏感性、特异性和诊断比值比（DOR）。采用汇总受试者工作特征（SROC）曲线分析和曲线下面积（AUC）来估计总体检验性能。
结果
本荟萃分析纳入了6项研究，共521例CRC患者和379例健康对照。对于miR-92a，预测CRC患者的汇总敏感性、特异性和DOR分别为76%（95%置信区间[CI]：72%-79%）、64%（95%置信区间[CI]：59%-69%）和8.05（95%CI：3.50-18.56）。此外，miR-92a诊断CRC的AUC为0.7720。
结论
微小RNA-92a可能是结直肠癌诊断中的一种新的潜在生物标志物，需要更多研究来突出其理论优势。
Zotero 插件